In a deal valued at up to $1 billion, Roche has licensed rights to a DLL3-directed antibody-drug conjugate (ADC) from China's ...

The start-up – founded by investment group Flagship Pioneering – said that OPL-0401 did not meet either the primary or ...

The current rate is a 2.7% gain on diagnosis rates seen before the pandemic and is equivalent to an additional 7,000 early ...

But with cancer remaining as one of the most prevalent and deadly forms of disease worldwide, there are a staggering number ...

The first of three phase 3 trials of Neumora Therapeutics' novel antidepressant navacaprant has ended in failure, wreaking ...

Hutchmed has agreed to divest its share of a Chinese joint venture company through a pair of deals that will give it a cash ...

The shape of BenevolentAI following the return of co-founder Ken Mulvany has started to crystallise and could see the company return to private hands. The UK specialist in applying artificial ...

Eversana has acquired pharmaphorum parent Healthware Group in a move that elevates the longstanding partnership between the companies, expands their geographic reach, and furthers their ambition ...

Otsuka and Click Therapeutics’ Rejoyn has become the first prescription digital therapeutic (DTx) to be approved by the FDA for people with major depressive disorder. Rejoyn (formerly CT-152), a ...

AbbVie has made another bolt-on deal in the immunology and inflammation category, paying $48 million upfront for rights to an antibody in preclinical development at OSE Immunotherapeutics.

An experimental therapy for Parkinson's disease being developed by Roche and Prothena has missed the mark in a phase 2b trial ...

Shares in Axsome Therapeutics have rocketed on FDA approval of its depression therapy Auvelity (formerly AXS-05) – a year after its approval was held up by the regulator. The FDA has cleared ...